SG10201913124RA - Methods for enhancing efficacy of therapeutic immune cells - Google Patents

Methods for enhancing efficacy of therapeutic immune cells

Info

Publication number
SG10201913124RA
SG10201913124RA SG10201913124RA SG10201913124RA SG10201913124RA SG 10201913124R A SG10201913124R A SG 10201913124RA SG 10201913124R A SG10201913124R A SG 10201913124RA SG 10201913124R A SG10201913124R A SG 10201913124RA SG 10201913124R A SG10201913124R A SG 10201913124RA
Authority
SG
Singapore
Prior art keywords
methods
immune cells
therapeutic immune
enhancing efficacy
efficacy
Prior art date
Application number
SG10201913124RA
Inventor
Dario Campana
Takahiro Kamiya
Original Assignee
Nat Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56564429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201913124R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nat Univ Singapore filed Critical Nat Univ Singapore
Publication of SG10201913124RA publication Critical patent/SG10201913124RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/05—Fusion polypeptide containing a localisation/targetting motif containing a GOLGI retention signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
SG10201913124RA 2015-02-06 2016-02-05 Methods for enhancing efficacy of therapeutic immune cells SG10201913124RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562112765P 2015-02-06 2015-02-06
US201562130970P 2015-03-10 2015-03-10

Publications (1)

Publication Number Publication Date
SG10201913124RA true SG10201913124RA (en) 2020-03-30

Family

ID=56564429

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201706236SA SG11201706236SA (en) 2015-02-06 2016-02-05 Methods for enhancing efficacy of therapeutic immune cells
SG10201913124RA SG10201913124RA (en) 2015-02-06 2016-02-05 Methods for enhancing efficacy of therapeutic immune cells

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201706236SA SG11201706236SA (en) 2015-02-06 2016-02-05 Methods for enhancing efficacy of therapeutic immune cells

Country Status (18)

Country Link
US (4) US10765699B2 (en)
EP (2) EP4134430A1 (en)
JP (4) JP6895380B2 (en)
KR (1) KR20170109052A (en)
CN (4) CN115029362A (en)
AU (2) AU2016216149B2 (en)
CA (1) CA2975851A1 (en)
DK (1) DK3253865T3 (en)
ES (1) ES2926384T3 (en)
HR (1) HRP20220890T1 (en)
HU (1) HUE059662T2 (en)
LT (1) LT3253865T (en)
PL (1) PL3253865T3 (en)
PT (1) PT3253865T (en)
RS (1) RS63574B1 (en)
SG (2) SG11201706236SA (en)
SI (1) SI3253865T1 (en)
WO (1) WO2016126213A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948462A1 (en) 2014-05-15 2015-11-19 National University Of Singapore Modified natural killer cells and uses thereof
SG11201706236SA (en) * 2015-02-06 2017-08-30 Nat Univ Singapore Methods for enhancing efficacy of therapeutic immune cells
JP7237449B2 (en) 2015-02-27 2023-03-13 アイセル・ジーン・セラピューティクス・エルエルシー Construction of Chimeric Antibody Receptors (CARs) Targeting Hematologic Tumors and Methods of Use
KR20230091191A (en) 2016-05-27 2023-06-22 아게누스 인코포레이티드 Anti-tim-3 antibodies and methods of use thereof
WO2018081978A1 (en) * 2016-11-03 2018-05-11 深圳华大基因研究院 Method and system for improving gene editing efficiency
CN110268049A (en) * 2016-11-22 2019-09-20 新加坡国立大学 CD7 for T cell malignant tumour immunotherapy expresses retarding agent and Chimeric antigen receptor
WO2018156434A1 (en) 2017-02-22 2018-08-30 H. Lee Moffitt Cancer Center And Research Institute Inc. Tim3-binding chimeric antigen receptors
WO2018169922A2 (en) * 2017-03-13 2018-09-20 Kite Pharma, Inc. Chimeric antigen receptors for melanoma and uses thereof
CN110636851B (en) 2017-03-27 2023-11-03 新加坡国立大学 Truncated NKG2D chimeric receptor and use thereof in natural killer cell immunotherapy
JP7270253B2 (en) 2017-03-27 2023-05-10 ナショナル ユニヴァーシティ オブ シンガポール Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
US11648269B2 (en) 2017-08-10 2023-05-16 National University Of Singapore T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
CA3079076A1 (en) * 2017-10-18 2019-04-25 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Methods and compounds for improved immune cell therapy
CN111132701A (en) 2017-10-25 2020-05-08 锕医药股份有限公司 anti-CD45-based conditioning methods and their use in combination with gene editing cell-based therapies
AU2018396083A1 (en) * 2017-12-29 2020-05-21 Cellectis Method for improving production of CAR T cells
CA3089478A1 (en) * 2018-01-25 2019-08-01 Pdi Therapeutics, Inc. Mica/b antibodies and methods of use
CN108314739B (en) * 2018-02-05 2020-07-14 深圳市默赛尔生物医学科技发展有限公司 Multi-signal chimeric antigen receptor, expression gene thereof, NK cell modified by multi-signal chimeric antigen receptor and application of NK cell
TW202000238A (en) * 2018-02-26 2020-01-01 比利時商艾伯林克斯公司 Improved nucleotide sequences encoding peptide linkers
KR20200138741A (en) * 2018-04-02 2020-12-10 내셔널 유니버시티 오브 싱가포르 Neutralization of human cytokines using membrane-bound anti-cytokine non-signaling binding agents expressed in immune cells
JP2021525068A (en) * 2018-05-23 2021-09-24 ナショナル ユニバーシティ オブ シンガポール Blocking CD2 surface expression and expressing chimeric antigen receptor for immunotherapy of T cell malignancies
JP2021525530A (en) * 2018-06-01 2021-09-27 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ Suppression of cytokine release syndrome using chimeric antigen receptor cell therapy
CN109207430A (en) * 2018-09-25 2019-01-15 华东师范大学 A kind of Chimeric antigen receptor NK cell and its preparation method and application
CN109266618B (en) * 2018-10-18 2021-04-23 赛元生物科技(杭州)有限公司 Macrophage capable of targeting tumor cells and preparation method thereof
KR20200049594A (en) * 2018-10-24 2020-05-08 주식회사 툴젠 Manipulated immune cell
CN109652379B (en) * 2018-12-29 2022-08-16 博生吉医药科技(苏州)有限公司 CD7 chimeric antigen receptor modified NK-92MI cell and application thereof
MX2021010670A (en) 2019-03-05 2021-11-12 Nkarta Inc Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy.
JOP20210298A1 (en) 2019-05-14 2023-01-30 Provention Bio Inc Methods and compositions for preventing type 1 diabetes
GB201914611D0 (en) * 2019-10-09 2019-11-20 Autolus Ltd Engineered immune cell
CN113005088A (en) * 2019-12-19 2021-06-22 苏州方德门达新药开发有限公司 Engineered T cells, their preparation and use
CN113088495A (en) * 2020-01-09 2021-07-09 苏州方德门达新药开发有限公司 Engineered T cells, their preparation and use
CN112195155A (en) * 2020-08-11 2021-01-08 广东万海细胞生物科技有限公司 Universal CAR-T cell and preparation method thereof
CN114525259A (en) * 2020-11-03 2022-05-24 南京北恒生物科技有限公司 Chimeric antigen receptor targeting CD7 and uses thereof
CA3201499A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
EP4259782A1 (en) * 2020-12-14 2023-10-18 Allogene Therapeutics, Inc. Methods and reagents for characterizing car t cells for therapies
CA3202218A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CN113416701B (en) * 2021-07-28 2023-05-09 新疆西部赛澳生物科技有限责任公司 NK cell culture medium and culture method
CN116731205B (en) * 2023-05-19 2024-02-27 皖南医学院第一附属医院（皖南医学院弋矶山医院） Immunopotentiating fusion protein for expressing TGF beta RII and TIM3 extracellular region and application thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3785186T2 (en) 1986-09-02 1993-07-15 Enzon Lab Inc BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
DE69233528T2 (en) 1991-11-25 2006-03-16 Enzon, Inc. Process for the preparation of multivalent antigen-binding proteins
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
EP1015616A2 (en) 1997-09-19 2000-07-05 Dana Farber Cancer Institute, Inc. Intrabody-mediated control of immune reactions
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
AU2002220265A1 (en) * 2000-11-03 2002-05-15 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
AU2002361390A1 (en) 2001-12-14 2003-06-30 Friedrich-Alexander-Universitaet Erlangen-Nuernberg Anti-cd7 immunotoxin as fusion protein
US20090191213A9 (en) 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
DK1673397T3 (en) 2003-07-02 2011-03-07 Univ Genova Method for Preparation and Evaluation of Cytotoxicity of KIR2DL NK Receptors Antibodies
WO2005017163A2 (en) * 2003-08-15 2005-02-24 Imperial College Innovations Limited Phenotypic knockout of cell-surface proteins
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
JP5112863B2 (en) 2004-07-01 2013-01-09 ノヴォ ノルディスク アー／エス Human anti-KIR antibody
US20060121043A1 (en) * 2004-10-27 2006-06-08 Medimmune, Inc. Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections
EP1835929B8 (en) 2005-01-06 2016-07-27 Novo Nordisk A/S Anti-kir combination treatments and methods
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
CA2625998C (en) * 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
JP5174005B2 (en) * 2006-03-28 2013-04-03 ハンプトン ユニバーシティ Hadron treatment plan with appropriate biological weighting
PL2132229T3 (en) * 2007-03-01 2016-12-30 Recombinant anti-epidermal growth factor receptor antibody compositions
ES2424745T3 (en) * 2007-09-07 2013-10-08 Agensys, Inc. Antibodies and related molecules that bind to 24P4C12 proteins
BRPI0908508A2 (en) 2008-01-24 2016-03-22 Novo Nordisk As humanized anti-human nkg2a monoclonal antibody
ES2826883T3 (en) * 2009-10-14 2021-05-19 Janssen Biotech Inc Antibody affinity maturation methods
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
DK3214091T3 (en) * 2010-12-09 2019-01-07 Univ Pennsylvania USE OF CHEMICAL ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CANCER
PL2800811T3 (en) 2012-05-25 2017-11-30 Emmanuelle Charpentier Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
BR112015000660A8 (en) * 2012-07-13 2022-03-15 Childrens Hospital Philadelphia use of a first-line therapy and a second-line therapy for treating a patient having a disease, disorder or condition associated with elevated tumor antigen expression, and a composition for reducing or preventing an adverse effect associated with administering a genetically modified cell to express a car.
HUE050797T2 (en) * 2012-10-10 2021-01-28 Sangamo Therapeutics Inc T cell modifying compounds and uses thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
KR101521224B1 (en) * 2012-12-20 2015-05-19 한양대학교 산학협력단 Humanized single chain fragment antibody(scFv) carrier specific for T cell
EP2938627B1 (en) * 2012-12-27 2019-03-20 Aduro Biotech, Inc. Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
EP3985028A1 (en) * 2013-02-06 2022-04-20 Celgene Corporation Modified t lymphocytes having improved specificity
DK3004337T3 (en) 2013-05-29 2017-11-13 Cellectis Method for constructing T cells for immunotherapy using RNA-guided Cas nuclease system
PT3071222T (en) * 2013-11-21 2020-11-20 Ucl Business Plc Cell
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
CN107075483A (en) 2014-07-15 2017-08-18 朱诺治疗学股份有限公司 The engineered cell treated for adoptive cellular
JP2017531430A (en) 2014-10-07 2017-10-26 セレクティスＣｅｌｌｅｃｔｉｓ Method for modulating the activity of immune cells induced by CAR
CN114836385A (en) 2014-10-31 2022-08-02 宾夕法尼亚大学董事会 Altering gene expression in CART cells and uses thereof
CA2970440A1 (en) * 2014-12-24 2016-06-30 Ucl Business Plc Cell co-expressing chimeric antigen receptors binding cd19 and cd22
SG11201706236SA (en) * 2015-02-06 2017-08-30 Nat Univ Singapore Methods for enhancing efficacy of therapeutic immune cells
JP7237449B2 (en) 2015-02-27 2023-03-13 アイセル・ジーン・セラピューティクス・エルエルシー Construction of Chimeric Antibody Receptors (CARs) Targeting Hematologic Tumors and Methods of Use
BR112017018770A2 (en) * 2015-03-02 2018-04-17 Innovative Cellular Therapeutics CO., LTD. reduced immune tolerance induced by pd-l1
EP3310915A4 (en) 2015-06-19 2019-04-10 Massachusetts Institute of Technology Tumor immunotherapy
MA42895A (en) 2015-07-15 2018-05-23 Juno Therapeutics Inc MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
WO2017023801A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
CN108697736A (en) 2015-10-06 2018-10-23 明尼苏达大学董事会 Therapeutic composition and method
US20180371052A1 (en) 2015-12-22 2018-12-27 Icell Gene Therapeutics Llc Chimeric antigen receptors and enhancement of anti-tumor activity
US11390658B2 (en) 2016-06-06 2022-07-19 St. Jude Children's Research Hospital Anti-CD7 chimeric antigen receptor and method of use thereof
EP3474867A4 (en) 2016-06-24 2020-05-20 iCell Gene Therapeutics LLC Chimeric antigen receptors (cars), compositions and methods thereof
CA2937157A1 (en) 2016-07-25 2018-01-25 Ucl Business Plc Protein-based t-cell receptor knockdown
CA3032429A1 (en) 2016-08-03 2018-02-08 Washington University Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
CN110268049A (en) 2016-11-22 2019-09-20 新加坡国立大学 CD7 for T cell malignant tumour immunotherapy expresses retarding agent and Chimeric antigen receptor
GB201622044D0 (en) 2016-12-22 2017-02-08 Ucl Business Plc T cell-targeted T cells
WO2018132479A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation Modified t cells and methods of their use
US11648269B2 (en) 2017-08-10 2023-05-16 National University Of Singapore T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
EP3864052A4 (en) 2018-11-14 2022-07-27 Medisix Therapeutics Pte Ltd. Two-gene vectors for generating car-t cells and uses thereof

Also Published As

Publication number Publication date
US20180008638A1 (en) 2018-01-11
AU2022204601A1 (en) 2022-07-21
CN113713091A (en) 2021-11-30
CN115029362A (en) 2022-09-09
EP3253865A4 (en) 2018-10-24
CN107709548B (en) 2022-06-28
AU2016216149B2 (en) 2022-03-31
CN107709548A (en) 2018-02-16
JP2018507685A (en) 2018-03-22
PL3253865T3 (en) 2022-10-10
EP3253865A1 (en) 2017-12-13
US20220370501A1 (en) 2022-11-24
JP7320560B2 (en) 2023-08-03
HRP20220890T1 (en) 2022-10-14
RS63574B1 (en) 2022-10-31
EP4134430A1 (en) 2023-02-15
EP3253865B1 (en) 2022-06-22
JP6895380B2 (en) 2021-06-30
DK3253865T3 (en) 2022-08-15
ES2926384T3 (en) 2022-10-25
LT3253865T (en) 2022-11-10
CN114891816A (en) 2022-08-12
US10765699B2 (en) 2020-09-08
HUE059662T2 (en) 2022-12-28
US20210046112A1 (en) 2021-02-18
US20220347219A1 (en) 2022-11-03
JP2021137024A (en) 2021-09-16
SG11201706236SA (en) 2017-08-30
KR20170109052A (en) 2017-09-27
US11679132B2 (en) 2023-06-20
JP2023153141A (en) 2023-10-17
JP2023153142A (en) 2023-10-17
AU2016216149A1 (en) 2017-08-17
SI3253865T1 (en) 2022-10-28
PT3253865T (en) 2022-10-03
CA2975851A1 (en) 2016-08-11
WO2016126213A1 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
SG10201913124RA (en) Methods for enhancing efficacy of therapeutic immune cells
HK1245829A1 (en) Methods for controlled elimination of therapeutic cells
IL283258A (en) Treatment of hypoparathyroidism
IL258931A (en) Therapeutic compounds and methods
HK1258062A1 (en) Methods of administering elagolix
HUE051354T2 (en) Therapeutic
HK1252695A1 (en) Improved methods and compounds for eliminating immune responses to therapeutic agents
GB201512365D0 (en) Novel therapy
IL285882A (en) Therapeutic uses of l-4-chlorokynurenine
HK1258994A1 (en) Methods for treatment of diseases
GB201410216D0 (en) Therapeutic
GB201522223D0 (en) Therapeutic T cells
GB201510637D0 (en) Therapeutic
GB201505382D0 (en) Novel therapy
GB201512139D0 (en) Methods of treatment
GB201516068D0 (en) Novel therapy
GB201407837D0 (en) Methods of cancer therapy
GB201518805D0 (en) Therapy
GB201506944D0 (en) Therapeutic treatment
HUP1500253A2 (en) Therapeutic energy disc
GB201418508D0 (en) Therapeutic
GB201413719D0 (en) Therapeutic
GB201410832D0 (en) Therapeutic
GB201410334D0 (en) Therapeutic
GB201406674D0 (en) Therapeutic